← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Dynavax Technologies Corporation
Berkeley, CA
$35,184,154
Total funding
17
Grants
Funding over time
peak $10.3M · FY2005–17$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$35,184,154 · 17
By mechanism
N01$16,861,540 · 1
U01$11,514,341 · 4
R43$3,336,309 · 8
R44$2,823,296 · 2
R21$425,278 · 1
R41$223,390 · 1
Investigators at Dynavax Technologies Corporation
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
Largest grants
Adjuvant Development Program$9,711,242
N01 · FY2011 · AI
Adjuvant Development Program$3,227,796
N01 · FY2008 · AI
Adjuvant Development Program$2,248,871
N01 · FY2012 · AI
Advanced anthrax vaccine made with ISS DNA formulations$2,098,735
U01 · FY2006 · AI
ISS-linked NP vaccine to control pandemic flu outbreak$1,767,169
U01 · FY2006 · AI
Adjuvant Development Program$1,673,631
N01 · FY2009 · AI
Production of an NP-ISS conjugate vaccine to combat pandemic influenza.$1,616,687
U01 · FY2008 · AI
Production of an NP-ISS conjugate vaccine to combat pandemic influenza.$1,600,000
U01 · FY2007 · AI
Development of an inhibitory oligonucleotide for the treatment of lupus$932,510
R44 · FY2009 · AI
Development of an inhibitory oligonucleotide for the treatment of lupus$878,519
R44 · FY2008 · AI
Advanced anthrax vaccine made with ISS DNA formulations$816,464
U01 · FY2005 · AI
Immunostimulatory DNA Priming of Lung Innate Immunity$759,577
U01 · FY2004 · AI
Immunostimulatory DNA Priming of Lung Innate Immunity$739,815
U01 · FY2003 · AI
Developing small molecule inhibitors of TLR8 for treatment of rheumatoid arthritis$589,482
R44 · FY2016 · AI
ISS-linked NP vaccine to control pandemic flu outbreak$534,847
U01 · FY2005 · AI
Advanced anthrax vaccine made with ISS DNA formulations$456,128
U01 · FY2004 · AI
Developing small molecule inhibitors of TLR8 for treatment of rheumatoid arthritis$422,785
R44 · FY2017 · AI
ISS-linked NP vaccine to control pandemic flu outbreak$382,199
U01 · FY2004 · AI
Inhibitors of Toll-like receptors 7 & 9 for treatment of skin inflammation$360,909
R43 · FY2010 · AI
Inhibitors of Toll-like receptors 7 & 9 for treatment of skin inflammation$359,430
R43 · FY2009 · AI